Table S16 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

September 2, 2025Open Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

The validation process confirms the utility of a genomic test for assessing malignancy in melanocytic tumors, enhancing diagnostic accuracy.
Key evidence from clinical follow-up highlights the importance of this genomic test in patients with borderline conventional tumors.
The approach utilizes observational data to analyze genomic indicators in conjunction with clinical follow-up assessments.
This finding may enable a more accurate diagnosis of malignancy in melanoma, impacting clinical decision-making.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Observational analysis validates a genomic test for malignancy in borderline melanoma cases, suggesting important clinical implications.

Patients with borderline conventional tumors and available clinical followup

No takes yet. Share an insight, caveat, or question.

Vergara et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share